vs
Bio-Techne（TECH）与登士柏西诺德（XRAY）财务数据对比。点击上方公司名可切换其他公司
登士柏西诺德的季度营收约是Bio-Techne的3.2倍（$961.0M vs $295.9M）。Bio-Techne净利率更高（12.8% vs -15.2%，领先28.0%）。登士柏西诺德同比增速更快（6.2% vs -6.4%）。过去两年Bio-Techne的营收复合增速更高（4.2% vs 0.4%）
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
登士柏西诺德是美国牙科设备及耗材制造商，业务覆盖全球120多个国家，在21个国家设有生产工厂。该公司前身为1993年Gendex公司以5.9亿美元收购登士柏国际后整合组建的企业，是全球牙科领域的重要供应商。
TECH vs XRAY — 直观对比
营收规模更大
XRAY
是对方的3.2倍
$295.9M
营收增速更快
XRAY
高出12.6%
-6.4%
净利率更高
TECH
高出28.0%
-15.2%
两年增速更快
TECH
近两年复合增速
0.4%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $295.9M | $961.0M |
| 净利润 | $38.0M | $-146.0M |
| 毛利率 | 64.6% | 46.1% |
| 营业利润率 | 18.4% | -14.5% |
| 净利率 | 12.8% | -15.2% |
| 营收同比 | -6.4% | 6.2% |
| 净利润同比 | 68.3% | 66.0% |
| 每股收益（稀释后） | $0.24 | $-0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收TECHXRAY
| Q4 25 | $295.9M | $961.0M | ||
| Q3 25 | — | $904.0M | ||
| Q2 25 | $317.0M | $936.0M | ||
| Q1 25 | $316.2M | $879.0M | ||
| Q4 24 | $297.0M | $905.0M | ||
| Q3 24 | $289.5M | $951.0M | ||
| Q2 24 | $306.1M | $984.0M | ||
| Q1 24 | $303.4M | $953.0M |
净利润TECHXRAY
| Q4 25 | $38.0M | $-146.0M | ||
| Q3 25 | — | $-427.0M | ||
| Q2 25 | $-17.7M | $-45.0M | ||
| Q1 25 | $22.6M | $20.0M | ||
| Q4 24 | $34.9M | $-430.0M | ||
| Q3 24 | $33.6M | $-494.0M | ||
| Q2 24 | $40.6M | $-4.0M | ||
| Q1 24 | $49.1M | $18.0M |
毛利率TECHXRAY
| Q4 25 | 64.6% | 46.1% | ||
| Q3 25 | — | 48.8% | ||
| Q2 25 | 62.7% | 52.4% | ||
| Q1 25 | 67.9% | 53.0% | ||
| Q4 24 | 65.3% | 49.3% | ||
| Q3 24 | 63.2% | 52.1% | ||
| Q2 24 | 66.4% | 51.9% | ||
| Q1 24 | 67.4% | 53.1% |
营业利润率TECHXRAY
| Q4 25 | 18.4% | -14.5% | ||
| Q3 25 | — | -24.1% | ||
| Q2 25 | -7.5% | -13.7% | ||
| Q1 25 | 12.2% | 7.2% | ||
| Q4 24 | 16.0% | -56.2% | ||
| Q3 24 | 13.8% | -48.6% | ||
| Q2 24 | 15.0% | 5.1% | ||
| Q1 24 | 22.1% | 4.4% |
净利率TECHXRAY
| Q4 25 | 12.8% | -15.2% | ||
| Q3 25 | — | -47.2% | ||
| Q2 25 | -5.6% | -4.8% | ||
| Q1 25 | 7.1% | 2.3% | ||
| Q4 24 | 11.7% | -47.5% | ||
| Q3 24 | 11.6% | -51.9% | ||
| Q2 24 | 13.3% | -0.4% | ||
| Q1 24 | 16.2% | 1.9% |
每股收益（稀释后）TECHXRAY
| Q4 25 | $0.24 | $-0.74 | ||
| Q3 25 | — | $-2.14 | ||
| Q2 25 | $-0.11 | $-0.22 | ||
| Q1 25 | $0.14 | $0.10 | ||
| Q4 24 | $0.22 | $-2.09 | ||
| Q3 24 | $0.21 | $-2.46 | ||
| Q2 24 | $0.26 | $-0.02 | ||
| Q1 24 | $0.31 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $172.9M | $326.0M |
| 总债务越低越好 | $260.0M | $2.3B |
| 股东权益账面价值 | $2.0B | $1.3B |
| 总资产 | $2.5B | $5.4B |
| 负债/权益比越低杠杆越低 | 0.13× | 1.70× |
8季度趋势，按日历期对齐
现金及短期投资TECHXRAY
| Q4 25 | $172.9M | $326.0M | ||
| Q3 25 | — | $363.0M | ||
| Q2 25 | $162.2M | $359.0M | ||
| Q1 25 | $140.7M | $398.0M | ||
| Q4 24 | $177.5M | $272.0M | ||
| Q3 24 | $187.5M | $296.0M | ||
| Q2 24 | $152.9M | $279.0M | ||
| Q1 24 | $145.3M | $291.0M |
总债务TECHXRAY
| Q4 25 | $260.0M | $2.3B | ||
| Q3 25 | — | — | ||
| Q2 25 | $346.0M | — | ||
| Q1 25 | $330.0M | — | ||
| Q4 24 | $300.0M | $1.7B | ||
| Q3 24 | $300.0M | — | ||
| Q2 24 | $319.0M | — | ||
| Q1 24 | $389.0M | — |
股东权益TECHXRAY
| Q4 25 | $2.0B | $1.3B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | $1.9B | $2.0B | ||
| Q1 25 | $2.0B | $2.0B | ||
| Q4 24 | $2.1B | $1.9B | ||
| Q3 24 | $2.1B | $2.5B | ||
| Q2 24 | $2.1B | $3.1B | ||
| Q1 24 | $2.0B | $3.3B |
总资产TECHXRAY
| Q4 25 | $2.5B | $5.4B | ||
| Q3 25 | — | $5.7B | ||
| Q2 25 | $2.6B | $6.1B | ||
| Q1 25 | $2.6B | $6.0B | ||
| Q4 24 | $2.7B | $5.8B | ||
| Q3 24 | $2.7B | $6.6B | ||
| Q2 24 | $2.7B | $6.9B | ||
| Q1 24 | $2.7B | $7.1B |
负债/权益比TECHXRAY
| Q4 25 | 0.13× | 1.70× | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | 0.16× | — | ||
| Q4 24 | 0.14× | 0.90× | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 0.19× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $101.0M |
| 自由现金流经营现金流 - 资本支出 | — | $60.0M |
| 自由现金流率自由现金流/营收 | — | 6.2% |
| 资本支出强度资本支出/营收 | — | 4.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $104.0M |
8季度趋势，按日历期对齐
经营现金流TECHXRAY
| Q4 25 | — | $101.0M | ||
| Q3 25 | — | $79.0M | ||
| Q2 25 | $98.2M | $48.0M | ||
| Q1 25 | $41.1M | $7.0M | ||
| Q4 24 | $84.3M | $87.0M | ||
| Q3 24 | $63.9M | $141.0M | ||
| Q2 24 | $75.5M | $208.0M | ||
| Q1 24 | $81.0M | $25.0M |
自由现金流TECHXRAY
| Q4 25 | — | $60.0M | ||
| Q3 25 | — | $40.0M | ||
| Q2 25 | $93.3M | $16.0M | ||
| Q1 25 | $31.0M | $-12.0M | ||
| Q4 24 | $77.5M | $36.0M | ||
| Q3 24 | $54.7M | $98.0M | ||
| Q2 24 | $57.5M | $156.0M | ||
| Q1 24 | $64.5M | $-9.0M |
自由现金流率TECHXRAY
| Q4 25 | — | 6.2% | ||
| Q3 25 | — | 4.4% | ||
| Q2 25 | 29.4% | 1.7% | ||
| Q1 25 | 9.8% | -1.4% | ||
| Q4 24 | 26.1% | 4.0% | ||
| Q3 24 | 18.9% | 10.3% | ||
| Q2 24 | 18.8% | 15.9% | ||
| Q1 24 | 21.3% | -0.9% |
资本支出强度TECHXRAY
| Q4 25 | — | 4.3% | ||
| Q3 25 | — | 4.3% | ||
| Q2 25 | 1.5% | 3.4% | ||
| Q1 25 | 3.2% | 2.2% | ||
| Q4 24 | 2.3% | 5.6% | ||
| Q3 24 | 3.2% | 4.5% | ||
| Q2 24 | 5.9% | 5.3% | ||
| Q1 24 | 5.4% | 3.6% |
现金转化率TECHXRAY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.82× | 0.35× | ||
| Q4 24 | 2.42× | — | ||
| Q3 24 | 1.90× | — | ||
| Q2 24 | 1.86× | — | ||
| Q1 24 | 1.65× | 1.39× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
XRAY
| Essential Dental Solutions | $372.0M | 39% |
| Equipment And Instruments | $160.0M | 17% |
| Implants And Prosthetics | $150.0M | 16% |
| CADCAM | $139.0M | 14% |
| Wellspect Healthcare | $88.0M | 9% |
| Orthodontics | $52.0M | 5% |
